thalidomide has been researched along with Leukemoid Reaction in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Leukemoid Reaction: A peripheral blood picture resembling that of leukemia or indistinguishable from it on the basis of morphologic appearance alone. (Dorland, 27th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hassoun, H | 1 |
| Roshal, M | 1 |
| Sabari, J | 1 |
| Nguyen, J | 1 |
| Gao, Q | 1 |
| Devlin, SM | 1 |
| Landau, H | 1 |
| Lendvai, N | 1 |
| Chung, DJ | 1 |
| Lesokhin, AM | 1 |
| Korde, N | 1 |
| Mailankody, S | 1 |
| Dogan, A | 1 |
| Giralt, SA | 1 |
| Landgren, CO | 1 |
1 other study available for thalidomide and Leukemoid Reaction
| Article | Year |
|---|---|
Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Hematopoietic Stem Cell Transplantation; | 2017 |